Table 5.
The unified Parkinson disease rating scale III improvement (UPDRS III at therapy initiation minus UPDRS III at 12 months follow-up) assessment by univariate analyses, then in relation with therapy in multivariate regression, adjusted for age, Parkinson disease duration, treatment duration, Hoehn and Yahr stage at the beginning, and in stratified multivariate analysis by Hoehn and Yahr stage.
| Unstratified analyses | Stratified by Hoehn & Yahr = 3 | Stratified by Hoehn & Yahr = 4 | |||||||||||
| B | (95% CI) | P value | R2 | B adjusted∗ | (95% CI) | P value | B adjusted∗∗ | (95% CI) | P value | B adjusted∗∗ | (95% CI) | P value | |
| Age (years) | −0.22 | (−0.51–0.07) | .138 | 0.04 | -0.2 | (−0.31–-0.08) | .001 | −0.14 | (−0.24–0.03) | .010 | −0.33 | (−0.58–0.07) | .014 |
| Parkinson's disease duration (years) | 0.68 | (0.35–1.02) | <.001 | 0.23 | 0.12 | (−0.07–0.3) | .209 | 0.07 | (−0.14–0.27) | .500 | 0.14 | (−0.19–0.46) | .385 |
| Treatment duration (years) | 0.12 | (−0.98–1.23) | .824 | 0.001 | -0.26 | (−0.74–0.22) | .285 | −0.06 | (−0.66–0.54) | .827 | −0.28 | (−1.06–0.49) | .461 |
| Hoehn and Yahr stage at the beginning | 10.79 | (6.57–15.02) | <.001 | 0.32 | −0.54 | (−3.33–2.25) | −.54 | – | – | – | – | – | – |
| Therapy (intrajejunal vs oral) | 18.14 | (15.99–20.29) | <.001 | 0.84 | 17.76 | (14.92–20.6) | 17.76 | 15.6 | (12.01–19.18) | <.001 | 18.35 | (13.84–22.87) | <.001 |
| Adjusted R2 | 0.86 | 0.78 | 0.81 | ||||||||||